Buy Areplivir tablets 200mg No. 40 online. Free worldwide shipping. PayPal payment.
Brand: PROMOMED RUS, LLC
Drug form: Film-coated tablets
Manufacturers: Russia
Active substance: Favipiravir
Group: Antiviral agent
Expiration date: 2 years
We accept payments through Paypal which guarantees our customers the protection of theirs funds in case of any possible delivery issues.
We undertake all fees for the delivery and currency exchange. Read more about customer protection:
https://www.paypal.com/us/webapps/mpp/paypal-safety-and-security
Feel free to contact us in case of any questions: manager@befitpharma.com
AREPLIVIR (Favipiravir) tablets 200mg No. 40
Indications for use of are:
Treatment for a new coronavirus infection (COVID-19)
Pharmachologic effect:
This medicinal product is registered under the registration procedure for medicinal products intended for use in conditions of threat of occurrence, occurrence and elimination of emergency situations. The instruction was prepared based on the limited amount of clinical data on the use of the drug and will be supplemented as new data becomes available. The use of the drug is possible only in inpatient medical care.
Antiviral drug.
Antiviral activity in vitro:
Favipiravir has antiviral activity against laboratory strains of influenza A and B viruses (EC50 0.014-0.55 μg / ml).
For strains of influenza A and B viruses resistant to adamantane (amantadine and rimantadine), oseltamivir or zanamivir, the EC50 is 0.03-0.94 μg / ml and 0.09-0.83 μg / ml, respectively. For influenza A strains (including strains resistant to adamantane, oseltamivir and zanamivir) such as type A swine influenza and type A avian influenza, including highly pathogenic strains (including H5N1 and H7N9), the EC50 is 0.06-3.53 μg / ml.
Favipiravir inhibits the SARS-CoV-2 virus, which causes the new coronavirus infection (COVID-19). The EC50 in Vero E6 cells is 61.88 μmol, which corresponds to 9.72 μg / ml.
Mechanism of action:
Favipiravir is metabolized in cells to favipiravir ribosyl triphosphate (Favipiravir RTF) and selectively inhibits RNA-dependent RNA polymerase involved in influenza virus replication. RTF favipiravir (1000 μmol / L) showed no inhibitory effect on human αDNA, but showed an inhibitory effect in the range from 9.1 to 13.5% on β and in the range from 11.7 to 41.2% on human γDNA. The inhibitory concentration (IC50) of RTF favipiravir for human RNA polymerase II was 905 μmol / L.
Resistance:
After 30 passages in the presence of favipiravir, no changes were observed in the susceptibility of influenza type A viruses to favipiravir, and no resistant strains were observed either. In clinical studies, the emergence of influenza viruses resistant to favipiravir was not detected.
Pharmacokinetics:
Favipiravir is readily absorbed from the gastrointestinal tract. Tmax 1.5 hours. Plasma protein binding is about 54%. Favipiravir is mainly metabolized by aldehyde oxidase and partially metabolized to the hydroxylated form by xanthine oxidase. RTF of favipiravir is metabolized in cells. Of other metabolites, in addition to hydroxylate, glucuronate conjugate was also recorded in human blood plasma and urine. It is excreted mainly by the kidneys in the form of an active metabolite of hydroxylate, a small amount - unchanged. T1 / 2 about 5 hours
In patients with mild and moderate hepatic insufficiency (class A and B according to the Child-Pugh classification), an increase in Cmax and AUC was observed by 1.5 times and 1.8 times, respectively, compared with healthy volunteers. In patients with severe hepatic impairment (class C according to the Child-Pugh classification), Cmax and AUC increased 2.1 times and 6.3 times, respectively.
In patients with moderate renal failure (GFR <60 ml / min and ≥30 ml / min), the residual concentration of favipiravir (Ctrough) increased 1.5-fold compared with patients without renal impairment. Favipiravir has not been studied in patients with severe and end-stage renal failure (GFR <30 ml / min).